Prosthetic Joint Infection Treatment Market - Global Prosthetic Joint Infection Treatment Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2031 -

Description

Global prosthetic joint infection (PJI) market is poised for substantial growth, with experts projecting a robust Compound Annual Growth Rate (CAGR) of 6.85% from 2024 to 2031, leading to a market size of US$160 million by the end of the forecast period. This impressive growth is attributed to various factors including an ageing population, increased incidence of joint surgeries, technological advancements in treatment, and rising healthcare spending and patient awareness.

Market Growth Drivers

The increasing incidence of prosthetic joint surgeries worldwide, driven by factors such as an ageing population and the rising prevalence of conditions like osteoarthritis and rheumatoid arthritis, is contributing to a higher demand for effective PJI treatment solutions. Technological advancements, including advanced antimicrobial coatings for prosthetic devices and improved diagnostic techniques, are significant growth drivers. These advancements enhance treatment efficacy, leading to better patient outcomes, reduced hospital stays, and lower healthcare costs overall. Continuous investment in Research and Development (R&D) by healthcare companies is pivotal in propelling the market forward.

Major Growth Barriers

Despite promising growth prospects, the PJI market faces challenges such as high treatment costs, particularly in low-income regions, and the emergence of antibiotic-resistant bacteria. Limited awareness about PJI risks and restricted access to healthcare facilities hinder market growth in developing countries. Antibiotic resistance complicates treatment and innovation in the sector, leading to longer treatment times and increased healthcare costs.

Key Trends and Opportunities

Advanced diagnostics and personalized medicine are growing trends, enabling tailored antibiotic therapies for better treatment efficacy. The development and adoption of antibiotic-loaded bone cement and coatings for prosthetic joints are rising, offering high local concentrations of drugs while minimizing side effects. Expansion into developing markets presents growth opportunities, with a focus on developing cost-effective solutions. Investments in R&D for novel therapies and advancements in targeted drug delivery systems could revolutionize the market.

Regional Dynamics

North America maintains its dominant position in the prosthetic joint infection treatment market, owing to its high infection rates and advanced healthcare infrastructure. The region boasts a well-established network of healthcare facilities, research institutions, and pharmaceutical companies, facilitating the development and adoption of innovative PJI treatment solutions. Additionally, factors such as a large ageing population and the prevalence of conditions like osteoarthritis and rheumatoid arthritis contribute to the high demand for PJI treatments in the region.

Europe, while also a significant market player, emphasizes cost-effectiveness and affordability in its approach to PJI treatment. With a strong focus on healthcare sustainability and resource optimization, European countries invest in strategies aimed at delivering effective treatments while minimizing healthcare expenditures. This focus on cost-efficiency drives the adoption of standardized treatment protocols, generic medications, and value-based healthcare models.

In contrast, the Asia Pacific region presents an emerging market with immense growth potential in the PJI treatment sector. The region is characterized by a rapidly ageing population, particularly in countries like Japan, South Korea, and China, where the prevalence of age-related joint conditions is on the rise. Furthermore, the increasing popularity of medical tourism in countries like India, Thailand, and Singapore attracts patients from both within the region and beyond, stimulating demand for PJI treatment options. As healthcare infrastructure continues to improve and economic development accelerates, the Asia Pacific region is poised to witness significant advancements in PJI treatment technologies and access to care. Collaborations between local healthcare providers, international pharmaceutical companies, and government initiatives aimed at addressing healthcare disparities further contribute to the region's growth potential.

Competitive Analysis

The competitive Analysis of the prosthetic joint infection treatment market is highly competitive and fragmented, with several key players vying for market share. Leading companies include major pharmaceutical firms, medical device manufacturers, and biotech companies specializing in antimicrobial coatings and advanced diagnostics. Major growth strategies adopted by these entities include strategic partnerships and collaborations, acquisitions, and significant investments in R&D to develop novel therapies and diagnostics.

Some key companies are:

Pfizer Inc.
Novartis AG
Mylan N.V.
Teva Pharmaceuticals
Merck & Co.
Eli Lilly & Company
AstraZeneca PLC
Lupin Limited
Dr. Reddys Laboratories
Aurobindo Pharma Ltd.
GSK PLC
Sun Pharmaceutical Industries Ltd.
Cipla Ltd.

Global Prosthetic Joint Infection Treatment Market is Segmented as Below:

By Drug:

Aminoglycosides
Glycopeptides
Rifamycin
Lincosamide
Penicillin
Other Antibiotics

By Infection:

Pre-operative Infection
Post-operative Infection

By Route of Administration:

Oral
Intravenous

By Pathogen:

Staphylococcus Aureus
Coagulase-negative Staphylococcus
Candida Species
Enterococcus Species
Other Pathogens

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa

1. Executive Summary

1.1. Global Prosthetic Joint Infection Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, By Volume, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. Covid-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.8. PESTLE Analysis

3. Global Prosthetic Joint Infection Treatment Market Outlook, 2019 - 2031

3.1. Global Prosthetic Joint Infection Treatment Market Outlook, By Drug, Value (US$ Mn), 2019 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Aminoglycosides
  - 3.1.1.2. Glycopeptides
  - 3.1.1.3. Rifamycin
  - 3.1.1.4. Lincosamide
  - 3.1.1.5. Penicillin
  - 3.1.1.6. Other Antibiotics
3.2. Global Prosthetic Joint Infection Treatment Market Outlook, By Infection, Value (US$ Mn), 2019 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Pre-operative Infection
  - 3.2.1.2. Post-operative Infection
3.3. Global Prosthetic Joint Infection Treatment Market Outlook, By Pathogen, Value (US$ Mn), 2019 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Staphylococcus aureus
  - 3.3.1.2. Coagulase-negative Staphylococcus
  - 3.3.1.3. Candida species
  - 3.3.1.4. Enterococcus species
  - 3.3.1.5. Other Pathogens
3.4. Global Prosthetic Joint Infection Treatment Market Outlook, By Route of Administration, Value (US$ Mn), 2019 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Oral
  - 3.4.1.2. Intravenous
3.5. Global Prosthetic Joint Infection Treatment Market Outlook, By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 3.5.1. Key Highlights
  - 3.5.1.1. Hospital Pharmacies
  - 3.5.1.2. Retail Pharmacies
  - 3.5.1.3. Drug Stores
  - 3.5.1.4. Online Sales
3.6. Global Prosthetic Joint Infection Treatment Market Outlook, By Region, Value (US$ Mn), 2019 - 2031
- 3.6.1. Key Highlights
  - 3.6.1.1. North America
  - 3.6.1.2. Europe
  - 3.6.1.3. Asia Pacific
  - 3.6.1.4. Latin America
  - 3.6.1.5. Middle East & Africa

4. North America Prosthetic Joint Infection Treatment Market Outlook, 2019 - 2031

4.1. North America Prosthetic Joint Infection Treatment Market Outlook, By Drug, Value (US$ Mn), 2019 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Aminoglycosides
  - 4.1.1.2. Glycopeptides
  - 4.1.1.3. Rifamycin
  - 4.1.1.4. Lincosamide
  - 4.1.1.5. Penicillin
  - 4.1.1.6. Other Antibiotics
4.2. North America Prosthetic Joint Infection Treatment Market Outlook, By Infection, Value (US$ Mn), 2019 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Pre-operative Infection
  - 4.2.1.2. Post-operative Infection
4.3. North America Prosthetic Joint Infection Treatment Market Outlook, By Pathogen, Value (US$ Mn), 2019 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Staphylococcus aureus
  - 4.3.1.2. Coagulase-negative Staphylococcus
  - 4.3.1.3. Candida species
  - 4.3.1.4. Enterococcus species
  - 4.3.1.5. Other Pathogens
4.4. North America Prosthetic Joint Infection Treatment Market Outlook, By Route of Administration, Value (US$ Mn), 2019 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Oral
  - 4.4.1.2. Intravenous
4.5. North America Prosthetic Joint Infection Treatment Market Outlook, By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 4.5.1. Key Highlights
  - 4.5.1.1. Hospital Pharmacies
  - 4.5.1.2. Retail Pharmacies
  - 4.5.1.3. Drug Stores
  - 4.5.1.4. Online Sales
4.6. North America Prosthetic Joint Infection Treatment Market Outlook, By Country, Value (US$ Mn), 2019 - 2031
- 4.6.1. Key Highlights
  - 4.6.1.1. U.S. Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 4.6.1.2. U.S. Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 4.6.1.3. U.S. Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 4.6.1.4. U.S. Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 4.6.1.5. U.S. Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 4.6.1.6. Canada Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 4.6.1.7. Canada Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 4.6.1.8. Canada Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 4.6.1.9. Canada Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 4.6.1.10. Canada Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 4.6.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Prosthetic Joint Infection Treatment Market Outlook, 2019 - 2031

5.1. Europe Prosthetic Joint Infection Treatment Market Outlook, By Drug, Value (US$ Mn), 2019 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Aminoglycosides
  - 5.1.1.2. Glycopeptides
  - 5.1.1.3. Rifamycin
  - 5.1.1.4. Lincosamide
  - 5.1.1.5. Penicillin
  - 5.1.1.6. Other Antibiotics
5.2. Europe Prosthetic Joint Infection Treatment Market Outlook, By Infection, Value (US$ Mn), 2019 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Pre-operative Infection
  - 5.2.1.2. Post-operative Infection
5.3. Europe Prosthetic Joint Infection Treatment Market Outlook, By Pathogen, Value (US$ Mn), 2019 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Staphylococcus aureus
  - 5.3.1.2. Coagulase-negative Staphylococcus
  - 5.3.1.3. Candida species
  - 5.3.1.4. Enterococcus species
  - 5.3.1.5. Other Pathogens
5.4. Europe Prosthetic Joint Infection Treatment Market Outlook, By Route of Administration, Value (US$ Mn), 2019 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Oral
  - 5.4.1.2. Intravenous
5.5. Europe Prosthetic Joint Infection Treatment Market Outlook, By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Hospital Pharmacies
  - 5.5.1.2. Retail Pharmacies
  - 5.5.1.3. Drug Stores
  - 5.5.1.4. Online Sales
5.6. Europe Prosthetic Joint Infection Treatment Market Outlook, By Country, Value (US$ Mn), 2019 - 2031
- 5.6.1. Key Highlights
  - 5.6.1.1. Germany Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 5.6.1.2. Germany Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 5.6.1.3. Germany Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 5.6.1.4. Germany Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 5.6.1.5. Germany Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 5.6.1.6. U.K. Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 5.6.1.7. U.K. Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 5.6.1.8. U.K. Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 5.6.1.9. U.K. Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 5.6.1.10. U.K. Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 5.6.1.11. France Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 5.6.1.12. France Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 5.6.1.13. France Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 5.6.1.14. France Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 5.6.1.15. France Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 5.6.1.16. Italy Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 5.6.1.17. Italy Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 5.6.1.18. Italy Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 5.6.1.19. Italy Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 5.6.1.20. Italy Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 5.6.1.21. Russia Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 5.6.1.22. Russia Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 5.6.1.23. Russia Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 5.6.1.24. Russia Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 5.6.1.25. Russia Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 5.6.1.26. Rest of Europe Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 5.6.1.27. Rest of Europe Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 5.6.1.28. Rest of Europe Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 5.6.1.29. Rest of Europe Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 5.6.1.30. Rest of Europe Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 5.6.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Prosthetic Joint Infection Treatment Market Outlook, 2019 - 2031

6.1.Asia Pacific Prosthetic Joint Infection Treatment Market Outlook, By Drug, Value (US$ Mn), 2019 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Aminoglycosides
  - 6.1.1.2. Glycopeptides
  - 6.1.1.3. Rifamycin
  - 6.1.1.4. Lincosamide
  - 6.1.1.5. Penicillin
  - 6.1.1.6. Other Antibiotics
6.2. Asia Pacific Prosthetic Joint Infection Treatment Market Outlook, By Infection, Value (US$ Mn), 2019 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Pre-operative Infection
  - 6.2.1.2. Post-operative Infection
6.3. Asia Pacific Prosthetic Joint Infection Treatment Market Outlook, By Pathogen, Value (US$ Mn), 2019 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Staphylococcus aureus
  - 6.3.1.2. Coagulase-negative Staphylococcus
  - 6.3.1.3. Candida species
  - 6.3.1.4. Enterococcus species
  - 6.3.1.5. Other Pathogens
6.4. Asia Pacific Prosthetic Joint Infection Treatment Market Outlook, By Route of Administration, Value (US$ Mn), 2019 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Oral
  - 6.4.1.2. Intravenous
6.5. Asia Pacific Prosthetic Joint Infection Treatment Market Outlook, By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. Hospital Pharmacies
  - 6.5.1.2. Retail Pharmacies
  - 6.5.1.3. Drug Stores
  - 6.5.1.4. Online Sales
6.6. Asia Pacific Prosthetic Joint Infection Treatment Market Outlook, By Country, Value (US$ Mn), 2019 - 2031
- 6.6.1. Key Highlights
  - 6.6.1.1. China Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 6.6.1.2. China Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 6.6.1.3. China Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 6.6.1.4. China Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 6.6.1.5. China Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 6.6.1.6. Japan Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 6.6.1.7. Japan Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 6.6.1.8. Japan Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 6.6.1.9. Japan Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 6.6.1.10. Japan Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 6.6.1.11. South Korea Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 6.6.1.12. South Korea Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 6.6.1.13. South Korea Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 6.6.1.14. South Korea Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 6.6.1.15. South Korea Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 6.6.1.16. India Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 6.6.1.17. India Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 6.6.1.18. India Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 6.6.1.19. India Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 6.6.1.20. India Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 6.6.1.21. Southeast Asia Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 6.6.1.22. Southeast Asia Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 6.6.1.23. Southeast Asia Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 6.6.1.24. Southeast Asia Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 6.6.1.25. Southeast Asia Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 6.6.1.26. Rest of Asia Pacific Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 6.6.1.27. Rest of Asia Pacific Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 6.6.1.28. Rest of Asia Pacific Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 6.6.1.29. Rest of Asia Pacific Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 6.6.1.30. Rest of Asia Pacific Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 6.6.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Prosthetic Joint Infection Treatment Market Outlook, 2019 - 2031

7.1. Latin America Prosthetic Joint Infection Treatment Market Outlook, By Drug, Value (US$ Mn), 2019 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Aminoglycosides
  - 7.1.1.2. Glycopeptides
  - 7.1.1.3. Rifamycin
  - 7.1.1.4. Lincosamide
  - 7.1.1.5. Penicillin
  - 7.1.1.6. Other Antibiotics
7.2. Latin America Prosthetic Joint Infection Treatment Market Outlook, By Infection, Value (US$ Mn), 2019 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Pre-operative Infection
  - 7.2.1.2. Post-operative Infection
7.3. Latin America Prosthetic Joint Infection Treatment Market Outlook, By Pathogen, Value (US$ Mn), 2019 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Staphylococcus aureus
  - 7.3.1.2. Coagulase-negative Staphylococcus
  - 7.3.1.3. Candida species
  - 7.3.1.4. Enterococcus species
  - 7.3.1.5. Other Pathogens
7.4. Latin America Prosthetic Joint Infection Treatment Market Outlook, By Route of Administration, Value (US$ Mn), 2019 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Oral
  - 7.4.1.2. Intravenous
7.5. Latin America Prosthetic Joint Infection Treatment Market Outlook, By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Hospital Pharmacies
  - 7.5.1.2. Retail Pharmacies
  - 7.5.1.3. Drug Stores
  - 7.5.1.4. Online Sales
7.6. Latin America Prosthetic Joint Infection Treatment Market Outlook, By Country, Value (US$ Mn), 2019 - 2031
- 7.6.1. Key Highlights
  - 7.6.1.1. Brazil Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 7.6.1.2. Brazil Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 7.6.1.3. Brazil Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 7.6.1.4. Brazil Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 7.6.1.5. Brazil Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 7.6.1.6. Mexico Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 7.6.1.7. Mexico Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 7.6.1.8. Mexico Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 7.6.1.9. Mexico Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 7.6.1.10. Mexico Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 7.6.1.11. Rest of Latin America Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 7.6.1.12. Rest of Latin America Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 7.6.1.13. Rest of Latin America Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 7.6.1.14. Rest of Latin America Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 7.6.1.15. Rest of Latin Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Prosthetic Joint Infection Treatment Market Outlook, 2019 - 2031

8.1. Middle East & Africa Prosthetic Joint Infection Treatment Market Outlook, By Drug, Value (US$ Mn), 2019 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Aminoglycosides
  - 8.1.1.2. Glycopeptides
  - 8.1.1.3. Rifamycin
  - 8.1.1.4. Lincosamide
  - 8.1.1.5. Penicillin
  - 8.1.1.6. Other Antibiotics
8.2. Middle East & Africa Prosthetic Joint Infection Treatment Market Outlook, By Infection, Value (US$ Mn), 2019 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Pre-operative Infection
  - 8.2.1.2. Post-operative Infection
8.3. Middle East & Africa Prosthetic Joint Infection Treatment Market Outlook, By Pathogen, Value (US$ Mn), 2019 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Staphylococcus aureus
  - 8.3.1.2. Coagulase-negative Staphylococcus
  - 8.3.1.3. Candida species
  - 8.3.1.4. Enterococcus species
  - 8.3.1.5. Other Pathogens
8.4. Middle East & Africa Prosthetic Joint Infection Treatment Market Outlook, By Route of Administration, Value (US$ Mn), 2019 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Oral
  - 8.4.1.2. Intravenous
8.5. Middle East & Africa Prosthetic Joint Infection Treatment Market Outlook, By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. Hospital Pharmacies
  - 8.5.1.2. Retail Pharmacies
  - 8.5.1.3. Drug Stores
  - 8.5.1.4. Online Sales
8.6. Middle East & Africa Prosthetic Joint Infection Treatment Market Outlook, By Country, Value (US$ Mn), 2019 - 2031
- 8.6.1. Key Highlights
  - 8.6.1.1. GCC Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 8.6.1.2. GCC Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 8.6.1.3. GCC Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 8.6.1.4. GCC Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 8.6.1.5. GCC Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 8.6.1.6. South Africa Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 8.6.1.7. South Africa Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 8.6.1.8. South Africa Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 8.6.1.9. South Africa Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 8.6.1.10. South Africa Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 8.6.1.11. Egypt Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 8.6.1.12. Egypt Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 8.6.1.13. Egypt Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 8.6.1.14. Egypt Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 8.6.1.15. Egypt Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
  - 8.6.1.16. Rest of Middle East & Africa Prosthetic Joint Infection Treatment Market By Drug, Value (US$ Mn), 2019 - 2031
  - 8.6.1.17. Rest of Middle East & Africa Prosthetic Joint Infection Treatment Market By Infection, Value (US$ Mn), 2019 - 2031
  - 8.6.1.18. Rest of Middle East & Africa Prosthetic Joint Infection Treatment Market By Pathogen, Value (US$ Mn), 2019 - 2031
  - 8.6.1.19. Rest of Middle East & Africa Prosthetic Joint Infection Treatment Market By Route of Administration, Value (US$ Mn), 2019 - 2031
  - 8.6.1.20. Rest of Middle East & Africa Prosthetic Joint Infection Treatment Market By Distribution Channel, Value (US$ Mn), 2019 - 2031
- 8.6.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Product vs Application Heatmap
9.2. Manufacturer vs Application Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Pfizer Inc.
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Novartis AG
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Mylan N.V.
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Teva Pharmaceuticals
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Merck & Co.
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Eli Lilly & Company
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. AstraZeneca plc.
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Lupin Limited
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Business Strategies and Development
- 9.5.9. Dr Reddys Laboratories
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Product Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. Aurobindo Pharma Ltd
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Product Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development
- 9.5.11. GSK plc.
  - 9.5.11.1. Company Overview
  - 9.5.11.2. Product Portfolio
  - 9.5.11.3. Financial Overview
  - 9.5.11.4. Business Strategies and Development
- 9.5.12. Sun Pharmaceutical Industries Ltd.
  - 9.5.12.1. Company Overview
  - 9.5.12.2. Product Portfolio
  - 9.5.12.3. Financial Overview
  - 9.5.12.4. Business Strategies and Development
- 9.5.13. Cipla ltd.
  - 9.5.13.1. Company Overview
  - 9.5.13.2. Product Portfolio
  - 9.5.13.3. Financial Overview
  - 9.5.13.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations